Immunohistochemical analysis of 157 patients with newly diagnosed glioma and 63 with recurrent glioblastoma who relapsed during temozolomide (TMZ) chemotherapy showed that high BHLHE40 expression was significantly associated with high pathological tumor grade and poor response to TMZ [74]. Here, BHLHE40 is linked to central nervous system cancer.